DaVita Inc. $DVA Shares Sold by Vanguard Group Inc.

Key Points

• Vanguard trimmed its stake in DaVita by 1.7% in Q4 (sold 73,550 shares) but still holds 4,154,354 shares (~5.88%) worth about $472 million, while institutional investors own roughly 90.12% of the stock.
• Q1 beat and raised guidance: DaVita reported EPS of $2.87 (vs. $2.33 est.) and $3.42B revenue (+6% y/y) and lifted FY2026 adjusted EPS guidance to a 14.10–15.20 range (consensus ~14.16).
• Valuation and metric watch: the stock trades near its 52‑week high with a $10.49B market cap and a P/E of 15.84, but management reported a very negative return on equity (−413%), a balance‑sheet/returns anomaly investors should review.

Vanguard Group Inc. reduced its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 1.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,154,354 shares of the company's stock after selling 73,550 shares during the period. Vanguard Group Inc. owned about 5.88% of DaVita worth $471,976,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of DVA. Concurrent Investment Advisors LLC acquired a new position in DaVita in the 4th quarter valued at about $385,000. M&T Bank Corp lifted its position in shares of DaVita by 694.7% during the fourth quarter. M&T Bank Corp now owns 22,307 shares of the company's stock worth $2,534,000 after purchasing an additional 19,500 shares in the last quarter. Evergreen Capital Management LLC purchased a new position in shares of DaVita in the fourth quarter valued at approximately $210,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of DaVita by 2.8% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,420 shares of the company's stock valued at $1,297,000 after purchasing an additional 314 shares during the period. Finally, First Horizon Corp grew its holdings in shares of DaVita by 257.7% in the fourth quarter. First Horizon Corp now owns 1,928 shares of the company's stock valued at $219,000 after purchasing an additional 1,389 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company's stock.

DaVita Stock Up 1.9%

Shares of NYSE:DVA opened at $156.98 on Wednesday. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $159.42. The firm's 50 day moving average price is $151.30 and its 200 day moving average price is $131.73. The stock has a market cap of $10.49 billion, a price-to-earnings ratio of 15.84, a price-to-earnings-growth ratio of 0.54 and a beta of 0.84.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 EPS for the quarter, topping the consensus estimate of $2.33 by $0.54. DaVita had a net margin of 5.47% and a negative return on equity of 413.18%. The company had revenue of $3.42 billion during the quarter, compared to analysts' expectations of $3.36 billion. During the same quarter in the previous year, the business posted $2.00 EPS. The firm's revenue was up 6.0% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, equities analysts anticipate that DaVita Inc. will post 14.16 EPS for the current year.

Wall Street Analysts Forecast Growth

DVA has been the topic of a number of research reports. Zacks Research lowered shares of DaVita from a "strong-buy" rating to a "hold" rating in a report on Monday, April 6th. UBS Group boosted their price target on shares of DaVita from $186.00 to $190.00 and gave the stock a "buy" rating in a research note on Wednesday, February 4th. Truist Financial set a $158.00 price objective on DaVita in a research note on Thursday, February 5th. TD Cowen reiterated a "hold" rating on shares of DaVita in a report on Tuesday, February 3rd. Finally, Barclays boosted their target price on DaVita from $143.00 to $158.00 and gave the stock an "equal weight" rating in a research note on Tuesday, February 3rd. Two research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $166.50.

Key Stories Impacting DaVita

Here are the key news stories impacting DaVita this week:

• Positive Sentiment: Q1 beat — DaVita posted EPS of $2.87 and revenue of $3.42B (revenue +6% y/y), topping analysts’ estimates and showing solid top‑line growth. MarketBeat Q1 results
• Positive Sentiment: Raised FY 2026 outlook — management bumped annual adjusted profit guidance (EPS range of 14.10–15.20), signaling confidence in demand and margin execution. Reuters: DaVita lifts forecast
• Positive Sentiment: Operational commentary — CEO highlighted clinical excellence and operating rigor on the earnings release and call, reinforcing management’s message that results are durable and driven by steady service demand. PR Newswire: Q1 results
• Neutral Sentiment: Guidance vs. street — the new FY range roughly lines up with analyst expectations (consensus ~14.16 EPS), so the raise is supportive but not a dramatic upside surprise. MarketBeat analyst figures
• Neutral Sentiment: Earnings call detail — the transcript provides color on patient volumes, margin levers and capital allocation; useful for modeling but contains no major new strategic shift. Seeking Alpha: Q1 call transcript
• Negative Sentiment: Capital/returns metric oddity — reported a very negative return on equity (-413%), which can signal balance‑sheet effects (e.g., buybacks or negative equity) that investors should review in more detail. Zacks: Q1 beat and metrics

About DaVita

DaVita Inc NYSE: DVA is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.